Effect of Simvastatin on Plasma Homocysteine Levels and Its Modification by MTHFR C677T Polymorphism in Chinese Patients with Primary Hyperlipidemia
Corresponding Author
Shanqun Jiang
School of Life Sciences, Anhui University, Hefei, China
Institute of Biomedicine, Anhui Medical University, Hefei, China
Correspondence
Shanqun Jiang, PhD., School of Life Sciences, Anhui University, 3 Feixi Road, PO Box 41, Hefei 230039, China.
Tel.: 86-13956059590
Fax: 86-551-5107354
E-mail: [email protected]
Search for more papers by this authorQianru Chen
School of Life Sciences, Anhui University, Hefei, China
Search for more papers by this authorScott A. Venners
Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
Search for more papers by this authorGuisheng Zhong
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA
Search for more papers by this authorYi-Hsiang Hsu
Institute for Aging Research, HSL and Harvard Medical School, Boston, MA, USA
Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, MA, USA
Search for more papers by this authorHouxun Xing
Institute of Biomedicine, Anhui Medical University, Hefei, China
Search for more papers by this authorXiaobin Wang
The Mary Ann and J. Milburn Smith Child Health Research Program, Children's Memorial Hospital and Children's Memorial Research Center, Chicago, IL, USA
Search for more papers by this authorXiping Xu
Institute of Biomedicine, Anhui Medical University, Hefei, China
Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, IL, USA
Search for more papers by this authorCorresponding Author
Shanqun Jiang
School of Life Sciences, Anhui University, Hefei, China
Institute of Biomedicine, Anhui Medical University, Hefei, China
Correspondence
Shanqun Jiang, PhD., School of Life Sciences, Anhui University, 3 Feixi Road, PO Box 41, Hefei 230039, China.
Tel.: 86-13956059590
Fax: 86-551-5107354
E-mail: [email protected]
Search for more papers by this authorQianru Chen
School of Life Sciences, Anhui University, Hefei, China
Search for more papers by this authorScott A. Venners
Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
Search for more papers by this authorGuisheng Zhong
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA
Search for more papers by this authorYi-Hsiang Hsu
Institute for Aging Research, HSL and Harvard Medical School, Boston, MA, USA
Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, MA, USA
Search for more papers by this authorHouxun Xing
Institute of Biomedicine, Anhui Medical University, Hefei, China
Search for more papers by this authorXiaobin Wang
The Mary Ann and J. Milburn Smith Child Health Research Program, Children's Memorial Hospital and Children's Memorial Research Center, Chicago, IL, USA
Search for more papers by this authorXiping Xu
Institute of Biomedicine, Anhui Medical University, Hefei, China
Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, IL, USA
Search for more papers by this authorSummary
Objective
We investigate the effect of simvastatin on plasma homocysteine (Hcy) levels and whether genetic factor affects the effect of simvastatin.
Methods
A total of 338 patients with hyperlipidemia were enrolled. Simvastatin was orally administered at a dose of 20 mg/day for 8 weeks. Plasma Hcy levels were measured by high-performance liquid chromatography at baseline and after 8 weeks of treatment. Genotyping of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism was performed by TaqMan probe technique.
Results
Serum total Hcy levels were positively correlated with serum creatinine (r = 0.332, P < 0.001). Among total subjects, simvastatin treatment resulted in a significant reduction in serum Hcy levels after 8 weeks (−0.37 ± 2.21 μmol/L, P = 0.003), and this effect was dependent on the initial levels of serum Hcy. The individuals with 677TT genotype had a significantly higher baseline Hcy level and a greater change in Hcy levels. After stratification by body mass index (BMI), we observed a significant increase in Hcy levels among the TT genotype group in adjusted model (beta±SE: 2.64 ± 0.84 μmol/L; P = 0.002) among patients with BMI ≥ 25 (kg/m2).
Conclusions
Simvastatin can cause a marked decrease in plasma Hcy levels. MTHFR C677T genetic variant contributes to simvastatin's effects among Chinese subjects with primary hyperlipidemia.
Supporting Information
| Filename | Description |
|---|---|
| cdr12002-sup-0001-Figures.docWord document, 52 KB | Figure S1. Relationships between variables assessed by Pearson'ks correlation coefficient. Figure S1A. Serum total Hcy levels positively correlated with serum creatinine (r = 0.332, P < 0.001). Figure S1B. Serum total Hcy levels inversely correlated with change in Hcy after simvastatin treatment (r = −0.273, P < 0.001). Figure S1C. Change in Hcy treated with simvastatin was positively associated with change of creatinine levels (r = 0.127, P = 0.02). |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60: 1106–1113.
- 2Juskowa J, Bartłomiejczyk J, Paczek L, et al. Total homocysteine as a risk factor for vascular disease in renal transplant recipients. Transplant Proc 2002; 34: 576–579.
- 3O K, Lynn EG, Chung YH, Siow YL, Man RY, Choy PC. Homocysteine stimulates the production and secretion of cholesterol in hepatic cells. Biochim Biophys Acta 1998; 1393: 317–324.
- 4Bhandari U, Pathan RA, Kumar V, Khanna N. Ameliorative role of atorvastatin on methionine-induced hyperhomocysteinemia and hematological changes in albino rats. Indian J Exp Biol 2011; 49: 132–139.
- 5Nigam GK, Ansari MN, Bhandari U. Effect of rosuvastatin on methionine-induced hyperhomocysteinaemia and haematological changes in rats. Basic Clin Pharmacol Toxicol 2008; 103: 287–292.
- 6Stampfer MJ, Malinow MR, Willet WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. J Am Med Assoc 1992; 268: 877–881.
- 7Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000; 102: 1227–1232.
- 8Qujeq D, Omran TS, Hosini L. Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem 2001; 34: 97–101.
- 9Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol, 1999; 10: 543–559.
- 10Bao XM, Wu CF, Lu GP. Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling. Acta Pharmacol Sin 2009; 30: 1392–1398.
- 11Bao XM, Wu CF, Lu GP. Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK. Atherosclerosis 2010; 210: 114–121.
- 12Xu Z, Lu G, Wu F. Simvastatin suppresses homocysteine-induced apoptosis in endothelial cells: roles of caspase-3, cIAP-1 and cIAP-2. Hypertens Res 2009; 32: 375–380.
- 13Luftjohann D, Sigit JI, Locatelli S, von Bergmann K. High dose simvastatin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesterolemia. Atherosclerosis 2001; 155: 265–266.
- 14Vladimirova-Kitova LG, Deneva TI, Marinov B. Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. Cardiovasc Ther 2011; 29: 340–348.
- 15Kaya C, Cengiz SD, Berker B, Demirtaş S, Cesur M, Erdoğan G. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2009; 92: 635–642.
- 16Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003; 43: 825–830.
- 17MacMahon M, Kirkpatrick C, Cummings CE, Clayton A, Robinson PJ, Tomiak RH, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 2000; 10: 195–203.
- 18Giral P, Bruckert E, Jacob N, Chapman MJ, Foglietti M-J, Turpin G. Homocysteine and lipid lowering agents: a comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 2001; 154: 421–427.
- 19Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial—FAT). Cardiovasc Res 2001; 52: 290–298.
- 20Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002; 144: e6.
- 21Sunder-Plassmann G, Fodinger M. Genetic determinants of the homocysteine level. Kidney Int Suppl 2003; 84: S141–S144.
- 22Girelli D, Friso S, Trabetti E, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998; 91: 4158–4163.
- 23Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7–9.
- 24Xu YL, Zhang SC, Li JP, et al. The modification of MTHFR gene polymorphism effect of the correlation between serum folic acid and plasma homocysteine. Acta Universitatis Medicinalis Anhui, 2006; 41: 639–642.
- 25McNulty H, Pentieva K, Hoey L, Ward M. Homocysteine, B-vitamins and CVD. Proc Nutr Soc, 2008; 67: 232–237.
- 26Schroecksnadel K, Frick B, Winkler C, Wirleitner B, Weiss G, Fuchs D. Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells. Clin Chem Lab Med 2005; 43: 1373–1376.
- 27Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002; 53: 493–502.
- 28Knight SF, Yuan J, Roy S, Imig JD. Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol Renal Physiol 2010; 298: F86–F94.
- 29Jankowski P, Kawecka-Jaszcz K. Lipid-lowering drugs and homocysteine. A comparison between statins and other lipid-lowering drugs. Atherosclerosis 2004; 172: 191–194.
- 30Maitland-van der Zee AH, Lynch A, Boerwinkle E, et al. Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics 2008; 18: 651–656.
- 31Nieminen T, Knuuti J, Hämelahti P, et al. Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy. Vascul Pharmacol 2007; 47: 113–117.
- 32Fan FF, Huo Y, Wang X, Xu X, Wang BY, Xu XP, Li JP. Effect of enalapril on plasma homocysteine levels in patients with essential hypertension. J Zhejiang Univ Sci B 2010; 11: 583–591.
- 33Karatela RA, Sainani GS. Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J 2009; 61: 156–159.
- 34Human JA, Ubbink JB, Jerling JJ, et al. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 1997; 263: 67–77.
